Vanguard Group Inc. Has $229.91 Million Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Vanguard Group Inc. grew its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 40.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 34,009,994 shares of the company’s stock after purchasing an additional 9,737,196 shares during the quarter. Vanguard Group Inc. owned about 8.70% of Recursion Pharmaceuticals worth $229,908,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. increased its position in shares of Recursion Pharmaceuticals by 17.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company’s stock worth $12,789,000 after buying an additional 288,926 shares during the period. The Manufacturers Life Insurance Company grew its holdings in Recursion Pharmaceuticals by 11.7% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 124,654 shares of the company’s stock worth $821,000 after acquiring an additional 13,041 shares during the period. FMR LLC raised its position in shares of Recursion Pharmaceuticals by 2.1% in the 3rd quarter. FMR LLC now owns 8,363,530 shares of the company’s stock worth $55,116,000 after acquiring an additional 170,810 shares in the last quarter. MetLife Investment Management LLC lifted its stake in shares of Recursion Pharmaceuticals by 13.7% in the 3rd quarter. MetLife Investment Management LLC now owns 136,541 shares of the company’s stock valued at $900,000 after purchasing an additional 16,405 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Recursion Pharmaceuticals by 5.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 52,530 shares of the company’s stock valued at $346,000 after purchasing an additional 2,667 shares in the last quarter. Institutional investors own 89.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on RXRX. Leerink Partners lowered their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a report on Friday, February 28th. Needham & Company LLC reiterated a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. KeyCorp reduced their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Finally, Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $8.25.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX stock opened at $4.24 on Friday. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a fifty day simple moving average of $7.22 and a two-hundred day simple moving average of $6.95. Recursion Pharmaceuticals, Inc. has a 12 month low of $4.06 and a 12 month high of $12.36. The firm has a market capitalization of $1.70 billion, a PE ratio of -2.77 and a beta of 1.00.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The business had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company’s revenue was down 57.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.42) EPS. Analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.